Submit your email to push it up the queue
Actelion Ltd., a leading biopharmaceutical company headquartered in Switzerland (CH), has established itself as a pioneer in the treatment of pulmonary arterial hypertension (PAH) and other rare diseases. Founded in 1997, Actelion has achieved significant milestones, including its acquisition by Johnson & Johnson in 2017, which further solidified its market position. The company focuses on innovative therapies, with core products such as Tracleer, Opsumit, and Uptravi, each designed to improve the quality of life for patients suffering from PAH. Actelion's commitment to research and development sets it apart, as it continually seeks to address unmet medical needs in the industry. With a strong presence in Europe, North America, and Asia, Actelion Ltd. remains a key player in the biopharmaceutical landscape, recognised for its contributions to advancing healthcare solutions.
How does Actelion Ltd's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Actelion Ltd's score of 77 is higher than 87% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Actelion Ltd, headquartered in Switzerland (CH), currently does not have specific carbon emissions data available for recent years. The company is a current subsidiary of Johnson & Johnson, and as such, it inherits climate commitments and emissions data from its parent organisation. Actelion's climate initiatives are aligned with those of Johnson & Johnson, which has set ambitious targets for reducing greenhouse gas emissions across its operations. These targets are cascaded down to Actelion at a third-level corporate relationship. However, specific reduction targets or achievements for Actelion itself have not been disclosed. The company is involved in various sustainability initiatives, including participation in the Science Based Targets initiative (SBTi) and the CDP (formerly Carbon Disclosure Project), both of which are led by Johnson & Johnson. These initiatives aim to enhance transparency and accountability in climate action, although specific metrics for Actelion are not provided. In summary, while Actelion Ltd is committed to climate action through its association with Johnson & Johnson, detailed emissions data and specific reduction targets for the company remain unavailable.
Access structured emissions data, company-specific emission factors, and source documents
1990 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Scope 1 | 308,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 2 | 751,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 3 | - | - | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 00,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Actelion Ltd is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.